Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)

The Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) funding opportunity is administered by the National Institutes of Health within the U.S. Department of Health and Human Services. NIH is the primary federal agency responsible for conducting and supporting medical research to improve public health outcomes. This opportunity aligns with NIH’s mission to advance scientific knowledge and address major public health challenges, specifically focusing on the intersection of alcohol consumption and cancer risk at the population level. The program is cataloged under federal assistance listings related to alcohol research and cancer biology, reflecting its interdisciplinary nature. The purpose of this funding opportunity is to support research that examines and implements population-level strategies to reduce alcohol-related cancer risk. The program emphasizes increasing awareness of the link between alcohol use and cancer, shifting social norms around alcohol consumption, and developing or evaluating public policies that influence alcohol-related behaviors. Additionally, it encourages research into interventions that address both moderate and heavy drinking, as well as alcohol use disorder, from a cancer prevention and control perspective. Projects are expected to operate across multiple levels, including community, policy, and systems-based approaches. Funding is provided through the R01 grant mechanism, which typically supports discrete, specified research projects. While the exact funding amounts, award ceilings, and total program funding are not specified in the summary, R01 grants generally support multi-year research initiatives with defined scopes and deliverables. The funding instrument allows for clinical trials but does not require them, providing flexibility for applicants proposing observational, intervention, or policy-based studies. There is no cost sharing or matching requirement, reducing financial barriers for applicants. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of domestic and international entities. Eligible applicants include federal agencies, state and local governments, nonprofit organizations with or without 501(c)(3) status, institutions of higher education (both public and private), tribal governments and organizations, small businesses, and for-profit entities. Additional eligible entities include minority-serving institutions such as Historically Black Colleges and Universities, Hispanic-serving institutions, and Tribal Colleges and Universities, as well as faith-based and community-based organizations. Foreign organizations and U.S. territories are also eligible, supporting a global research perspective. The application process requires submission through standard NIH channels, typically via Grants.gov, followed by processing in NIH’s electronic systems. Applicants must prepare a full research proposal that includes scientific aims, methodology, budget justification, and compliance documentation. While no pre-application requirement such as a letter of intent is specified in the summary, applicants are encouraged to consult the full funding announcement for detailed submission instructions and requirements. Applications are evaluated based on NIH peer review criteria, including scientific merit, significance, innovation, investigator qualifications, and feasibility. The application window is open with a final submission deadline of January 7, 2027. The opportunity was originally posted on November 6, 2024, and last updated on March 31, 2025. Given the extended timeline, applicants have ample time to develop comprehensive proposals. NIH opportunities such as this often follow recurring cycles aligned with standard submission dates, although recurrence is not explicitly stated. For additional information or assistance, applicants may contact NIH Grants Information via email. Overall, this funding opportunity represents a significant federal investment in addressing alcohol-related cancer risk through evidence-based, population-level research.